News & Updates

Show Multimedia Only

Hitting OS endpoint reaffirms frontline daratumumab-VCd as SoC for AL amyloidosis

27 Dec 2024 by

The evidence supporting an upfront daratumumab-containing regimen as the SoC for AL amyloidosis is reaffirmed by the significant OS benefit demonstrated in the final analysis of ANDROMEDA

Hitting OS endpoint reaffirms frontline daratumumab-VCd as SoC for AL amyloidosis

27 Dec 2024

What are the risk factors for MACE, malignancy in rheumatoid arthritis?

25 Dec 2024

Factors such as male sex, older age, and prior X-ray examination are linked to an increased risk of major adverse cardiovascular events (MACE) and malignancies in patients with rheumatoid arthritis, according to a study from Japan.

What are the risk factors for MACE, malignancy in rheumatoid arthritis?

25 Dec 2024

Enzalutamide demonstrates modest activity in granulosa cell ovarian tumours

24 Dec 2024

The use of the antiandrogen enzalutamide in patients with granulosa cell ovarian tumour (GCT) falls short in terms of significant radiological response or clinical benefit, according to a phase II trial.

Enzalutamide demonstrates modest activity in granulosa cell ovarian tumours

24 Dec 2024

Imaging breakthrough holds promise for vascular imaging

23 Dec 2024 by

Researchers from the University College London (UCL) in the UK have developed a high-resolution three-dimensional (3D) photoacoustic scanner based on the Fabry-Perot (FP) ultrasound sensor concept and examined its potential as a tool for clinical vascular imaging.

Imaging breakthrough holds promise for vascular imaging

23 Dec 2024

Novel PD-1 inhibitor shows activity against PD-L1 positive recurrent or metastatic cervical cancer

22 Dec 2024

Enlonstobart, a fully humanized and high-affinity anti-PD-1 immunoglobulin G4 monoclonal antibody, shows therapeutic potential in patients with PD-L1 positive recurrent or metastatic cervical cancer (r/mCC), while having an acceptable safety profile, according to an open-label phase II study.

Novel PD-1 inhibitor shows activity against PD-L1 positive recurrent or metastatic cervical cancer

22 Dec 2024

Tislelizumab-chemo sustains PFS advantage over chemo alone at 3 years in recurrent/metastatic NPC

21 Dec 2024 by

With the follow-up extended for an additional year, the RATIONALE-309 trial demonstrates a continued PFS advantage following the addition of tislelizumab to chemo for the 1L treatment of recurrent/metastatic NPC, as shown in the 3-year follow-up results presented at ESMO Asia 2024

Tislelizumab-chemo sustains PFS advantage over chemo alone at 3 years in recurrent/metastatic NPC

21 Dec 2024

Original New Drug Application Approvals by US FDA (1-15 December 2024)

20 Dec 2024

New drug applications approved by US FDA as of 1-15 December 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 December 2024)

20 Dec 2024

FOLFOX plus nab-paclitaxel exceeds expected ORR, shows favourable haematotoxicity in gastric/GEJ adenocarcinoma

20 Dec 2024 by

An open-label single-arm phase II trial of FOLFOX and nab-paclitaxel (FOLFOX-A) reports a target-exceeding objective response rate (ORR) and a more favourable haematologic toxicity profile than triplet regimen historical controls in metastatic/advanced unresectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.

FOLFOX plus nab-paclitaxel exceeds expected ORR, shows favourable haematotoxicity in gastric/GEJ adenocarcinoma

20 Dec 2024

Ponsegromab a targeted therapy for cancer cachexia

19 Dec 2024 by

In patients with cancer cachexia and elevated levels of growth differentiation factor-15 (GDF-15), GDF-15 inhibition with ponsegromab led to a significant increase in body weight and overall activity level and reduction in cachexia symptoms, a phase II study suggests.

Ponsegromab a targeted therapy for cancer cachexia

19 Dec 2024

CameL at 5 years: 1L camrelizumab plus chemo maintains long-term OS benefit

19 Dec 2024 by

The 5-year update of the phase III CameL study of camrelizumab plus carboplatin and pemetrexed (C+CP) in patients with previously untreated advanced non-squamous non-small-cell lung cancer (NSCLC) without EGFR/ALK alterations demonstrates continued overall survival (OS) and progression-free survival (PFS) benefits.

CameL at 5 years: 1L camrelizumab plus chemo maintains long-term OS benefit

19 Dec 2024

News & Updates

Showing Oncology articles

Showing

Specialty:

Hitting OS endpoint reaffirms frontline daratumumab-VCd as SoC for AL amyloidosis

Hitting OS endpoint reaffirms frontline daratumumab-VCd as SoC for AL amyloidosis

What are the risk factors for MACE, malignancy in rheumatoid arthritis?

What are the risk factors for MACE, malignancy in rheumatoid arthritis?

Enzalutamide demonstrates modest activity in granulosa cell ovarian tumours

Enzalutamide demonstrates modest activity in granulosa cell ovarian tumours

Imaging breakthrough holds promise for vascular imaging

Imaging breakthrough holds promise for vascular imaging

Novel PD-1 inhibitor shows activity against PD-L1 positive recurrent or metastatic cervical cancer

Novel PD-1 inhibitor shows activity against PD-L1 positive recurrent or metastatic cervical cancer

Tislelizumab-chemo sustains PFS advantage over chemo alone at 3 years in recurrent/metastatic NPC

Tislelizumab-chemo sustains PFS advantage over chemo alone at 3 years in recurrent/metastatic NPC

Original New Drug Application Approvals by US FDA (1-15 December 2024)

Original New Drug Application Approvals by US FDA (1-15 December 2024)

FOLFOX plus nab-paclitaxel exceeds expected ORR, shows favourable haematotoxicity in gastric/GEJ adenocarcinoma

FOLFOX plus nab-paclitaxel exceeds expected ORR, shows favourable haematotoxicity in gastric/GEJ adenocarcinoma

Ponsegromab a targeted therapy for cancer cachexia

Ponsegromab a targeted therapy for cancer cachexia

CameL at 5 years: 1L camrelizumab plus chemo maintains long-term OS benefit

CameL at 5 years: 1L camrelizumab plus chemo maintains long-term OS benefit